Servier shared a post on LinkedIn:
“March marks Colorectal Cancer Awareness Month – also known as Blue March.
According to the World Health Organization, colorectal cancer is the third most common cancer type worldwide, with almost 2 million cases diagnosed in 2022. Colorectal cancer is the second most common cause of cancer death.
We have been committed to fighting cancer for many years. Oncology is a major therapeutic priority for us, accounting for close to 70% of our R and D investments.
We currently have a portfolio of 8 medicines available to healthcare professionals and patients. Our major investments in the cancer are demonstrated through our robust pipeline of 34 oncology R and D projects.
Learn more about colorectal cancer”
Other articles featuring Servier on OncoDaily.